Browsing Tag
ASX
164 posts
Electro Optic Systems (ASX: EOS) rockets 600 % as LAND 400-3 contract ignites defence sector momentum
Find out how Electro Optic Systems’ A$108 million LAND 400-3 win drives its 600 % ASX rally and reshapes Australia’s defence supply chain.
DXB rockets on Japan orphan drug win — can Dimerix finally deliver an FSGS breakthrough?
Dimerix (ASX: DXB) secures orphan drug designation in Japan for DMX-200, strengthening its global Phase 3 kidney trial program. Find out what’s next.
Carawine Resources set for ASX delisting after QGold wins court battle over compulsory buyout
QGold secures full control of Carawine Resources after Federal Court approval, ending a year-long dispute and paving the way for ASX delisting at AUD 0.11 per share.
Can Alterity Therapeutics’ penny stock (ASX: ATH) ride ATH434’s $2.4bn market potential to long-term gains?
Alterity Therapeutics eyes $2.4B peak sales for ATH434 in Multiple System Atrophy. Can this small-cap biotech turn clinical promise into commercial reality?
Is Emyria (ASX: EMD) stock ready to re-rate after Medibank funds its TRD program?
Emyria (ASX: EMD) secures Medibank backing for its TRD program, marking a milestone for insurer-funded mental health care. Can the stock sustain momentum?
Seven sectors up, four sectors down — the ASX winners and losers you need to know
Find out how ASX sectors moved on September 19, 2025 — healthcare and technology led the gains while telecoms and staples lagged.
Why Life360, NEXTDC, and SiteMinder are smashing records—and what it means for ASX tech
Life360, NEXTDC, and SiteMinder stocks hit record highs as ASX tech leads weekly gains. Find out what’s driving the rally and what investors should watch.
BCAL Diagnostics (ASX: BDX) shares rise after ClearNote deal — is this the turning point investors were waiting for?
BCAL Diagnostics (ASX: BDX) expands with ClearNote Health deal for ovarian and pancreatic cancer tests—can this pivot revive its struggling stock?
Is Paladin Energy building the next uranium giant with its A$300m PLS funding push?
Find out how Paladin Energy’s A$300M fully underwritten equity raising could reshape its PLS uranium project and impact PDN stock in 2025.
Polynovo stock falls as diabetes wound trial results spotlight NovoSorb promise
Polynovo (ASX: PNV) shares slipped 1.37% as NovoSorb diabetes wound trial results showed faster healing in large wounds. Can reimbursement shifts revive growth?